- Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- Nonfatal and fatal DOB (2, 5-dimethoxy-4-bromamphetamine) overdose2005 | Publication without faculty affiliation
- Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure2021 | Faculty of Medicine in Pilsen
- The Identification of Precursor Regulation Impact on the Methamphetamine Market and Public Health Indicators in the Czech Republic: Time Series Structural Break Analysis2020 | First Faculty of Medicine
- Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects2010 | Second Faculty of Medicine
- Rosuvastatin and cardio vascular events in patients undergoing hemodialysis +12009 | Faculty of Medicine in Hradec Králové
- Rosuvastatin and cardio vascular events in patients undergoing hemodialysis2009 | First Faculty of Medicine
- Long-term experience with implantable treprostinil pumps in pulmonary arterial hypertension2020 | First Faculty of Medicine
- Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics2016 | Publication without faculty affiliation
- Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients?2013 | Faculty of Medicine in Pilsen
- Polypill Strategy in Secondary Cardiovascular Prevention2022 | First Faculty of Medicine
- Early Angiography in Patients with Chronic Kidney Disease: A Collaborative Systematic Review2009 | Third Faculty of Medicine
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients2017 | First Faculty of Medicine
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease2017 | First Faculty of Medicine
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients2017 | Publication without faculty affiliation
- Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome The VISTA-16 Randomized Clinical Trial2014 | Third Faculty of Medicine
- Cardiovascular risk in rheumatic diseases2016 | First Faculty of Medicine
- An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials2012 | Third Faculty of Medicine
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- Updated criteria for resting ECG evaluation in preparticipation screening2017 | Second Faculty of Medicine
- Increased prognostic value of combined myocardial perfusion SPECT Imaging and the quantification of lung TI-201 uptake2002 | Publication without faculty affiliation
- Interhospital transport for primary angioplasty improves the long-term outcome of acute myocardial infarction compared with immediate thrombolysis in the nearest hospital (one-year follow-up of the PRAGUE-1 study)2003 | Central Library of Charles University, Third Faculty of Medicine
- Role of sitagliptin in the treatment of type 2 diabetes based on the results of the TECOS study2016 | Second Faculty of Medicine
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2019 | Publication without faculty affiliation
- Current view on percutaneous treatment of chronic stable coronary artery disease2015 | Publication without faculty affiliation
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease2016 | Publication without faculty affiliation
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease2016 | Publication without faculty affiliation